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Abstract
Background: HIV-1
+ individuals who, without therapy, conserve cellular anti-HIV-1 responses, present with high, stable
CD4
+ T-cell numbers, and control viral replication, facilitate analysis of atypical viro-immunopathology. In the absence of
universal definition, immune function in such HIV controllers remains an indication of non-progression.
Methodology/Principal Findings: CD4 T-cell responses to a number of HIV-1 proteins and peptide pools were assessed by
IFN-c ELISpot and lymphoproliferative assays in HIV controllers and chronic progressors. Thymic output was assessed by
sjTRECs levels. Follow-up of 41 HIV-1
+ individuals originally identified as ‘‘Long-term non-progressors’’ in 1996 according to
clinical criteria, and longitudinal analysis of two HIV controllers over 22 years, was also performed. HIV controllers exhibited
substantial IFN-c producing and proliferative HIV-1-specific CD4 T-cell responses to both recombinant proteins and peptide
pools of Tat, Rev, Nef, Gag and Env, demonstrating functional processing and presentation. Conversely, HIV-specific T-cell
responses were limited to IFN-c production in chronic progressors. Additionally, thymic output was approximately 19 fold
higher in HIV controllers than in age-matched chronic progressors. Follow-up of 41 HIV-1
+ patients identified as LTNP in
1996 revealed the transitory characteristics of this status. IFN-c production and proliferative T-cell function also declines in 2
HIV controllers over 22 years.
Conclusions: Although increased thymic output and anti-HIV-1 T-cell responses are observed in HIV controllers compared
to chronic progressors, the nature of nonprogressor/controller status appears to be transitory.
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Introduction
HIV-1 infection typically manifests as a chronic progression to
AIDS during which fully functional CD8
+ cytotoxic T-lymphocyte
(CTL) responses are gradually lost [1,2]. Lack of maintenance of
CTL function is at least in part dependent on loss of numbers and
function of antigen-specific CD4
+ helper T lymphocytes (HTL)
[2–5]. Despite successful suppression of viral replication by highly
active antiretroviral therapy (HAART), HIV-1-specific effector T-
cell function fails to be reconstituted [6].
In HIV-1
+ individuals viral replication, disease progression and
opportunistic infection inversely correlate with fully functional
virus-specific HTL and CTL responses [2,7]. The term ‘‘long-term
non-progressor’’ (LTNP) was originally used before the advent of
the viral load assay, to describe a clinically non-progressing HIV-
1
+ patient defined by the maintenance of a stable CD4 T-cell
count within the normal range (450–1650 cells/ml blood) for many
years, in the absence of antiretroviral therapy [2].
Quantification of HIV-1 viraemia revealed that the majority of
persons originally defined as LTNPs did not control viral
replication, and disease progression in these patients occurred
eventually, although less rapid than in typical HIV-1
+ individuals
[8]. However, a small number of LTNPs exhibited suppression of
viral replication to levels below the detection threshold of the viral
load assay. The control of viral replication occurs in some patients
for prolonged periods, and these are referred to as HIV controllers
(HIC). From a cohort of ,5,000 HIV-1
+ patients at the Chelsea
and Westminster Hospital [9] approximately 0.2% of the cohort
have been identified as HICs. Here we present data from six HICs
who at the time of sample collection mounted robust cytokine-
producing, proliferation competent HIV-1-specific CD4 and CD8
T-cell responses.
Many studies include HIV-1
+ individuals with atypical rates of
disease progression, but discrepancy in terminology and inclusion
criteria renders it difficult to compare results across studies. The
terms ‘‘LTNP’’, ‘‘Elite controller’’ and ‘‘HIV controller’’ are
PLoS ONE | www.plosone.org 1 May 2009 | Volume 4 | Issue 5 | e5474commonly used, but with varying criteria of definition; the more
stringent the criteria applied, the fewer patients included in the
study. Inconsistency in the definition of the nonprogressor is
illustrated by example papers which use similar terminology to
encompass patients with widely differing characteristics. ‘‘Nonpro-
gressors’’ have been defined as patients with lengths of HIV-1
infection of over 14 years [10], more than 12 years [11], more than
4 years, 9 months [12], or an undisclosed length of time [13].
Similar variability is observed in the CD4 counts used to define
nonprogressorswhichindifferentreportsishigherthan 500[10,11],
‘‘normal’’ (311–1830 cells/ml blood) [12], or 825–1588 cells/ml
blood [13]. Viral loads of patients characterised as nonprogressors
also vary greatly between cohorts, ranging from ,50 copies/ml
plasma[13],through,125[12],,1,000 [10] to104,000 copies/ml
plasma [11]. Individuals who suppress HIV-1 viral load to below
detection limit have been reported as immunologically distinct from
those with low level viraemia [4,14], advocating the importance of
viral load when defining patient groups.
Preliminary evaluation of both HIV-1-specific CD4
+ and CD8
+
T-cell responses in HICs has shown that IL-2- and IFN-c-
producing Th1 responses are good predictors of stable CD4
+ T-
cell counts and delayed disease progression [4,7]. Understanding
the mechanisms of generation and maintenance of fully functional
HIV-1-specific peripheral HTL and CTL responses in chronic
HIV-1 infection, similar to those observed in HICs, may be of
considerable importance for the development of new, and
improvement of existing therapies [2,4,7,15]. Novel, effective
immunotherapeutic interventions may enable viral control and
retard disease progression either in conjunction with or after
termination of HAART [2,15].
Until now, little has been reported on thymic output in adult
HICs, however data from long-term asymptomatic adolescents
showed that thymic activity was almost normal when compared to
age-matched HIV negative controls [16]. Analysis of TREC levels
in SIV
+ macaques revealed a strong correlation between thymic
output and non-progression to AIDS [17].
Six HICs were recently identified using the following criteria;
HIV-1
+ with absence of HIV-1 disease, continuous undetectable
viraemia and stable CD4 T-cell count within the normal range for
over 8 years, despite lack of anti-retroviral therapy [1,2]. Here we
report cross-sectional data of responses to HIV-1, and thymic
output from these six HICs compared to six HIV-1
+ HAART-
naı ¨ve and eight HAART-treated, chronically infected progressors.
Longitudinal data detailing the changes in anti-HIV-1 responses
over time observed in two HICs, diagnosed as HIV-1
+ for more
than 22 years, is presented along with description of proviral gag
sequencing data from one of these two HICs, at two time points. In
addition to this, we also report the current clinical status of a cohort
of 41 ‘‘LTNPs’’ initially identified using clinical criteria in 1996.
Methods
Study subjects and samples
Blood samples were collected from patients belonging to the
Chelsea and Westminster cohort (Table 1). Up to date clinical
information from 41 ‘‘LTNP’’ originally identified in 1996 was
compiled. Informed written consent and ethical approval was
obtained from the Riverside Research Ethics Committee for the
studies described (RREC1108). PBMC were isolated by density
gradient centrifugation [4,18].
Plasma viral RNA and lymphocyte subset quantification
Plasma viral load and enumeration of CD3
+, CD4
+ and CD8
+
T lymphocytes was conducted as described previously [4,18].
HIV-1 antigens and peptides
Recombinant HIV-1 antigens: rGag p24 (EVA620), rTat
(ARP672) and rEnv gp120 (EVA646) (all baculovirus derived),
rNef (EVA650; Bru strain expressed in E.coli) and rRev
(ARP663.2; from clade B Han2 isolate expressed in E.coli) were
used in cell culture at a final concentration of 10 mg/ml. The 11
Rev, 8 Tat, 20 Nef and 22 Gag p24 peptides were 20-mers
overlapping by 10aa and used at a final concentration of 5 mg/ml
(all NIBSC, Potters Bar, UK).
Proliferation assays
Lymphocyte proliferation of freshly isolated PBMC was
measured as described previously [4]. Results are expressed as
stimulation index (SI); the experimental result divided by the
background (negative control; PBMC and media only). A positive
response is defined as SI$3.
IFN-c ELISpot assay using HIV-1 overlapping-peptide
stimuli
IFN-c ELISpot was carried out as described previously on
freshly isolated PBMC [4,18]. Negative controls (cells only)
resulted in #16 spot forming cells (SFC)/10
6 PBMC. The
positive threshold for IFN-c production was defined as $20
SFC/10
6 PBMC after subtracting background [18]. Results from
triplicate wells were averaged with ,10% variation between
duplicates.
PCR analysis of sjTRECs to determine Thymic output
DNA from 5610
6 PBMC was extracted using the Puregene
DNA purification kit (Gentra, Flowgen, Staffordshire, UK). PCR
amplification [19], and quantification of sjTRECs were performed
as described previously [20,21].
Proviral gag sequencing
Genomic DNA was extracted from 5610
6 PBMC using
the Nucleon Genomic DNA Extraction Kit (Tepnel Life
Sciences) according to the manufacturer’s instructions. DNA
was stored at 50 ng/ml in RNAse/DNAse free water (Sigma)
at 220uC until required. Proviral gag was amplified by
nested PCR as described previously [22], and the resulting
1.45 kbp product was sequenced using ABI 3730xl and ABI
3130xl hardware.
Statistical analysis
GraphPad Prism v5.0 (San Diego, USA) was used for statistical
calculations. The Mann-Whitney test was used to compare
responses between patient groups, and the Wilcoxon signed rank
test was used to compare paired responses from the same patient
as appropriate. Significance was measured to a 95% confidence
interval (p,0.05).
Results
Transient nature of ‘‘LTNP’’ status
Follow-up of a cohort of 41 HIV-1
+ individuals originally
defined as ‘‘LTNP’’ in 1996 and identified according to clinical
criteria: CD4 count, length of infection and lack of opportunistic
infection, was undertaken [1]. Pre-HAART CD4 counts and VL
of these patients are presented in Figure 1. Over the course of
eleven years, all 41 patients no longer met HIC status, with
detectable viraemia and falling CD4 counts, and the entire cohort
is now being prescribed HAART – which concurs with studies
described by others [8].
T Cells in HIV-1 Control
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Responses in HICs
Significantly higher proliferative responses to HIV-1 Tat, Rev,
Gag, Env and Nef(all p,0.01) recombinant antigens were observed
in the six HICs compared to 6 viraemic and 8 aviraemic chronic
progressors (Figure 2A). The three patient cohorts were age- and
length of infection-matched (detailed in Table 1). In HICs the
proliferative responses to rTat, rNef, rRev and rEnv were similar,
however the responses to rRev and rNef were significantly lower
than those resulting from stimulation with rGag (p=0.0313)
(Figure 2A). This may be due to the lower antigenic load of
regulatory Rev and Nef compared to the capsid protein Gag p24.
Although close to the threshold of positivity, both the anti-rRev and
-rNef proliferative responses in HICs were above negative cut-off
and statistically significantly higher than the responses mounted by
HAART-naı ¨ve,viraemic chronic progressors (vCPs; p=0.0022 and
p=0.0043 respectively) and HAART-treated aviraemic chronic
progressors (aCPs; p=0.0024 and p=0.0007 respectively.
Figure 2A). All proliferative responses mounted by aCPs in response
to the HIV-1 antigens tested were below the threshold of positivity
(SI,3). The significantly higher IFN-c responses to Tat peptides
(Figure 2B), andproliferative responsesto rNef and rp24 (Figure2A)
by vCPs compared to aCPs may be due to the lower antigenic
burden in aCPs who are receiving successful HAART. It is of note
however that only 1 CP (vCP 2) mounted a positive proliferative
response which was only just above threshold (rp24 SI=4, rNef
SI=8). All other CPs mounted no proliferative responses to any of
the HIV-1 antigens tested.
In addition to proliferation, IFN-c was released when PBMCs
from HICs were stimulated with Tat and Rev peptides as well as
Table 1. Detailed description of characteristics of the study cohorts.
Patient ID Sex
CD4 Count,
cells/ml blood
CD8 Count,
cells/ml blood
HIV-1 RNA,
copies/ml plasma
HAART duration,
months
Time since HIV-1
+
diagnosis, years Age, years
HIC 1 M 722 916 ,50 None 8.4 44.8
HIC 2 M 977 946 ,50 None 15.2 37.6
HIC 3 M 850 665 ,50 None 16.5 51.6
HIC 4 F 1,331 1,107 ,50 None 9.1 28.5
HIC 5 M 588 1,225 ,50 None 15.9 60.2
HIC 6 M 1,222 1,299 ,50 None 7.6 26.9
Median 913.5 1,026.5 ,50 12.2 41.2
(range) (588–1,331) (665–1,299) (,50) (7.6–15.9) (26.9–60.2)
vCP 1 M 376 751 27,488 None 13.3 51.0
vCP 2 M 665 1,860 3,604 None 9.0 33.7
vCP 3 M 315 1,197 39,271 None 13.7 50.4
vCP 4 M 573 1,423 6,228 None 16.3 35.1
vCP 5 - 590 1,468 12,261 None - -
vCP 6 M 700 1,910 27,508 None 16.4 36.7
Median 581.5 1,445.5 19,874.5 13.7 36.7
(range) (315–700) (751–1,910) (3,604–39,271) (9.0–16.4) (33.7–51.0)
aCP 1 M 590 1115 ,50 14 1.7 30.6
aCP 2 M 442 1080.0 ,50 12 1.1 41.5
aCP 3 M 801 1319 ,50 64 19.6 57.5
aCP 4 M 838 872 ,50 97 19.8 53.1
aCP 5 M 995 1959 ,50 113 22.7 52.6
aCP 6 M 503 1701 ,50 102 11.6 64.3
aCP 7 M 464 1436 ,50 51 20.1 43.6
aCP 8 M 1247 972 ,50 93 11.7 43.9
Median 696 1217 ,50 78 15.6 48.2
(range) (442–1247) (872–1959) (,50) (12–113) (1.1–22.7) (30.6–64.3)
P value - 0.0152* 0.0931* - - 0.6623* 0.9307*
0.2284
# 0.1812
# 0.4908
# 0.3450
#
0.2448{ 0.5728{ 0.8329{ 0.2222{
HIC 2-2
{ M 1,027 1,424 ,50 None 21.8 44.2
HIC 2-3
1 M 895 1,142 ,50 None 22.2 44.6
HIC 5-2
{ M 442 288 ,50 None 22.5 66.8
- , data not available; P values between *HIC and vCP,
#HIC and aCP, {vCP and aCP; bold face indicates statistically significant difference measured to a 95% confidence
interval by the Mann-Whitney test;
{2
nd or
13
rd visit respectively.
doi:10.1371/journal.pone.0005474.t001
T Cells in HIV-1 Control
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significantly lower than HICs when Gag peptides were used
(p=0.0411), but similar with Tat, Rev and Nef peptide stimuli.
Aviraemic CPs (n=8) on successful HAART (Table 1) exhibited
significantly lower IFN-c production in response to Tat peptides
from the responses mounted by the vCPs and HICs, presented in
Figure 2 (both p values ,0.01). These results demonstrate a
distinction between the IFN-c producing and proliferative ability
of HIC CD4 T cells and the IFN-c-only responses observed in
chronic progressors [23,24], which does not appear to be
dependent on HIV-1 plasma viraemia as aCPs, with HAART-
suppressed viral load, as well as vCPs, fail to mount a
lymphoproliferative response to HIV-1 antigens.
Cumulative response to individual p24 Gag peptides
Stimulation with Gag peptides or recombinant protein elicited
the dominant anti-HIV-1 response in HICs, concurring with
previous data showing an inverse correlation of anti-Gag responses
to viral burden [25]. The IFN-c response (median: 611 SFC/10
6,
range: 152–2,012) was significantly higher in HICs than vCPs
(p=0.041) and HAART-treated aCPs (p=0.0168; Figure 2B).
The proliferative response to rGag (median: SI 34.5, range: 27–65)
was significantly higher than in vCPs (p=0.002) and aCPs
(p=0.0007; Figure 2A). Consequently the anti-Gag response was
investigated further.
The sum of the IFN-c responses to 22 individual p24
overlapping peptides was similar to that resulting from stimulation
with the Gag peptide pool and rGag antigen (Figure 2C).
Additionally, the sum of the lymphoproliferative responses to
individual peptides was similar to the proliferation that occurred in
response to rp24 (Figure 2D). These data suggest functional
internalisation, processing and presentation of exogenous antigen
by antigen presenting cells of these HICs. In contrast, previously
published data shows that the proliferative responses to individual
overlapping Gag peptides were absent in a cohort of chronically
infected HIV-1
+ patients [4].
Thymic output
TREC levels were detectable in the PBMCs of all six HICs and
levels of TRECs observed in cord blood lymphocytes were used as
a positive control (Figure 3A). TREC levels in the six HICs ranged
from 38,817 to 119,586 TRECs/5610
6 PBMC with an average
TREC level of 79,201.5/5610
6 PBMC – approximately 19 fold
higher than previously reported by ourselves in HAART-naı ¨ve
chronic progressors, using the same methodology, where only 48%
had detectable TREC levels (average: 4,200 TRECs/5610
6
PBMC, range: 22,463–10,863) (Figure 3B) [26]. The comparative
cohort of chronic progressors were age-matched to the six HICs
(p=0.3823; median age HIC 41.2 years, range 26.9–60.2; median
age chronic progressor 36.5 years, range 20.2–57.7) and the CD4
count was significantly higher in HICs than HAART-naı ¨ve CPs
(p,0.0001; HIC median 913.5 cells/ml blood, range 588–1331;
CP median 254.5 cells/ml blood, range 13–551).
Reduction in T-cell-mediated anti-HIV-1 responses in two
HICs
Two HICs identified as HIV-1
+ in 1984 and 1986 were assessed
for anti-HIV-1 T-cell-mediated responses at two and three time
points (respectively). Patient HIC 5 donated blood to our studies at
191 and 270 months (15.9 and 22.5 years respectively) after HIV-
1
+ diagnosis (Table 1). Blood samples were obtained from patient
HIC 2 at 182, 262 and 267 months (15.2, 21.8 and 22.2 years
respectively) post-HIV-1
+ diagnosis (Table 1).
IFN-c release in responses to overlapping HIV-1 Tat, Nef, Rev
and Gag peptide pools, and proliferative responses to recombinant
HIV-1 Tat, Nef, Rev, Gag and Env proteins are shown in
Figure 4A and B respectively.
The IFN-c response mounted by HIC 2 to Gag and Nef peptide
pools remained relatively constant over the three time points,
spanning 85 months (7.1 years), and the IFN-c responses to Tat
and Rev peptides decreased below positive threshold at month
262, but were then regained five months later (Figure 4A). In
contrast, the proliferative responses to all of the recombinant HIV-
1 proteins declined to below positive threshold for the assay (SI of
3) (Figure 4B). Patient HIC 5 also exhibited a loss of proliferative
response to rGag, rTat and rEnv, but maintained a positive
proliferative response to rNef, albeit greatly reduced (,22% of
previous proliferative response) (Figure 4B). The IFN-c responses
mounted by HIC 5 were largely conserved, with partial decrease
to Tat, Rev and Nef peptide pools, and an increase in response to
Gag (Figure 4A).
Figure 1. Follow up of 41 ‘‘LTNPs’’ over 132 months since
original identification using clinical criteria in 1996. (a) All
available pre-HAART data of CD4 T-cell counts for the cohort of 41
LTNPssinceidentification(normalrange450–1650 cells/ml blood,marked
with horizontal line). (b) All available pre-HAART data of plasma viral load
for the cohort of 41 LTNPs since identification. DL=detection limit of
assay. Data from each individual are plotted with different symbols and
regression lines indicate slopes. Once the patient initiates anti-retroviral
therapy their characteristics are no longer shown on the graphs.
doi:10.1371/journal.pone.0005474.g001
T Cells in HIV-1 Control
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Proviral p17 and p24 were sequenced from the PBMC of
patient HIC 2 at 262 and 267 months post HIV-1
+ diagnosis. The
sequence was compared to the HXB2 consensus sequence using
the online HIV database [www.hiv.lanl.gov]. At time point 262
months the sequence of proviral gag in the patient was 96% similar
to HXB2. Five months later the HIV-1 proviral gag sequence was
92% similar to HXB2, indicating that despite undetectable viral
load (,50 copies HIV-1 RNA/ml plasma), changes in proviral
sequence occurred, suggesting residual viral replication.
Discussion
Here we present data from a cohort of strictly defined HICs.
Proliferative and IFN-c responses in HICs were assessed by
stimulating PBMC with a range of HIV-1 proteins and peptides.
We describe HICs who currently retain both functional IFN-c and
lymphoproliferative responses to regulatory Tat, Rev and Nef, in
addition to structural Gag and Env. In contrast, HIV-1-specific
lymphoproliferative responses were absent in both viraemic and
HAART-suppressed aviraemic HIV-1
+ chronic progressors. The
presence of multi-functional anti-HIV-1 Nef-, Tat- and Rev-
specific T cells suggests Nef, Tat and Rev as potential additional
antigenic targets that correlate with viral control. Gag- and Nef-
specific T cells may differ, with a higher proportion of Gag-specific
effector-memory T cells displaying stronger survival potential,
however, presence of both proliferation competent and IL-2
producing HIV-1 Gag- and Nef-specific T cells have been
observed in controllers with stable CD4 counts [4].
Successful stimulation of proliferation of CD4
+ T cells with
recombinant proteins, demonstrates the retention of functional
antigen internalisation, processing and presentation, as well as the
proliferative ability of CD4
+ T cells in these HICs. Proliferative
and IFN-c responses of HICs to rGag p24 were shown to be
comparable to stimulation with individual 20 aa peptides, also
indicating functional presentation of exogenous antigen.
The preserved, functional response to the early stage protein
Tat appears to suggest a lack of Tat-associated viral escape in these
HICs, probably resulting from initiation and maintenance of
immune control at an early stage of infection. Anti-Rev and -Nef
responses mounted by the HICs, although significant, were
considerably lower than responses to other viral antigens tested.
This may be due to the lower antigenic burden of Rev and Nef,
compared to Gag, when viral load is undetectable. This is
Figure 2. Significantly higher lymphoproliferative responses to HIV-1 recombinant antigens mounted by HIV controllers (HIC)
compared to HIV-1
+ viraemic chronic progressors (vCP) and aviraemic chronic progressors (aCP) despite comparable IFN-c release
to HIV-1 peptide pools. Broad IFN-c and proliferative responses to HIV-1 Gag p24 in HICs. Box plots show the median with IQR indicated. Whiskers
represent the 10
th–90
th percentiles. The Mann-Whitney test was used to compare responses between patient groups, and the Wilcoxon signed rank
test to compare paired responses from the same patient. *p,0.05, **p,0.01, ***p,0.001. (a) Lymphoproliferative response to rTat, rRev, rNef, rp24
(Gag) and rgp120 (Env), from HICs (n=6), vCPs (n=6) and aCPs (n=8). The threshold for positivity (SI $3) is marked. (b) IFN-c release (spot forming
cells per million PBMC), from HICs (n=6), vCPs (n=6) and aCPs (n=8), in response to stimulation with Tat, Rev, Nef and Gag p24 overlapping
peptides. Data represent mean values of triplicate wells with ,10% variation among triplicates. The threshold of 20 SFC/10
6 PBMC is marked. (c)
Summation of IFN-c release in response to stimulation with individual overlapping Gag p24 peptides (1–22) compared to the response to the peptide
pool and rp24 protein. Data from two representative HICs is shown. (d) Summation of lymphoproliferative responses, of two representative HICs, to
stimulation with individual overlapping Gag p24 peptides (1–22) compared to the response to rp24 protein.
doi:10.1371/journal.pone.0005474.g002
T Cells in HIV-1 Control
PLoS ONE | www.plosone.org 5 May 2009 | Volume 4 | Issue 5 | e5474supported by the report of a positive correlation between plasma
viral load and the number of anti-Rev and -Nef responses [25]. It
is also of note that an overzealous anti-Rev response may exert
selection pressure which could lead to reduced Rev activity.
Consequently Gag and Env expression could be lowered, reducing
sensitivity to anti-Gag and -Env CTL responses [27], and possibly
contributing to the increased viral load and consequent disease
progression observed in chronically infected HIV-1
+ individuals.
The evidence that 41 previously defined LTNPs have, since
initial identification in 1996, all progressed, suggests that despite
maintaining clinical nonprogression for a number of years,
‘‘LTNP’’ status is not necessarily permanent [1][8]. Consequently
the salient issues to address are why and through which process
nonprogressor status is lost. We have observed in HICs that prior
to progression, there is a loss of anti-HIV-1 response [4]. Anti-Env
and -Nef responses appear to diminish first, with no apparent
immediate affect on viral load [4]. It appears that the subsequent
loss of the multi-functional, balanced anti-Gag response accom-
panied by loss of virological control, may result in increased
viraemia. These observations concur with the reported association
of anti-Gag responses with low viraemia, and responses to Env and
accessory and regulatory proteins (including Nef) with increased
viral load [3,25]. The longitudinal data from two HICs
demonstrates a loss of proliferative responses to HIV-1 antigens
over time. Fluctuation in IFN-c production to the peptides of
regulatory proteins Tat and Rev is observed in both patients, which
Figure 3. Higher levels of thymic output in HIV controllers (HIC)
compared to age-matched chronic progressors (CP). (a) Electro-
phoresis gel showing an example of TREC levels in PBMC of HIC4
compared to the positive control, cord blood. (b) TREC levels in PBMC of
6 HICs compared to previously published data of PBMC from chronic
progressors [26]. The two cohorts are age-matched (p=0.3823; median
age HIC 41.2 years, range 26.9–60.2; median age CP 36.5 years, range
20.2–57.7). The CD4 count was significantly higher in HICs than HAART
naı ¨ve CPs (p,0.0001; HIC median 913.5 cells/ml blood, range 588–1331;
CP median 254.5 cells/ml blood, range 13–551).
doi:10.1371/journal.pone.0005474.g003
Figure 4. Longitudinal analysis of T-cell mediated responses, to
HIV-1 antigens and peptides, by two HIV controllers over a 79
and 85 month period. Data is shown from two HICs; HIC 5 and HIC 2,
from two and three time points respectively. Data represent mean values
of triplicate wells with ,10% variation among triplicates. (a) IFN-c release
(spotformingcells/10
6PBMC)inresponsetostimulationwithTat,Rev,Nef
and Gag p24 overlapping peptides. The threshold of 20 SFC/10
6 PBMC is
marked. (b) Lymphoproliferative response to rTat, rRev, rNef, rp24 (Gag)
and rgp120 (Env). The threshold for positivity (SI $3) is marked.
doi:10.1371/journal.pone.0005474.g004
T Cells in HIV-1 Control
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Rev-specific CD4 T cells. However, it is of note that both of these
patients, to date, still suppress HIV-1 plasma load to below
detection limit, have normal CD4 T-cell counts and are not
receiving HAART. It remains to be seen whether the proliferative
responses originally observed 7–8 years ago will be reinitiated in the
future, or if these patients are on the verge of disease progression.
In addition to the demonstration of the dominance and breadth
of anti-Gag responses in HICs, the observation that the presence/
absence of an anti-p24 response appears to be the watershed
between viral control and progression reiterates the importance of
p24 Gag as an immunological target [4,25].
A multitude of host factors connected to disease progression are
reviewed in [28], however specific, unanimous definition of the
LTNP or the HIC remains to be established. As well as creation of
universal criteria for defining nonprogressors, further detailed
immunogenetic studies are necessary to investigate why such
patients eventually lose HIV-1-specific responses and progress to
chronic disease.
Failure of viral control after many years of nonprogression may
result from demise in thymic function. Compromised thymic
output [29], and a correlation of CD4 T-cell recovery following
ART initiation and thymic volume [30], has been reported in
chronic HIV-1
+ infection. This is in contrast with normal thymic
function in HICs presented here. Thymic atrophy, which occurs
with advancing age in healthy individuals, may play a role in the
eventual loss of viral control that has been observed in the cohort
of 41 ‘‘LTNP’’, due to the fact that after ,20 years of HIV-1
infection the cohort is an ageing one (median age 50.5 years, range
40.5–71.8 years). The lower levels of sjTRECs/5610
6 PBMC,
previously observed in chronic progressors, may not be due solely
to a reduction in thymic function, but also dilution of sjTRECs,
resulting from immune hyperactivation-induced proliferation in
these individuals [31,32]. However, the ratio between sjTRECs
(generated after many rounds of intrathymic proliferation) and
bTRECs (generated early in thymocyte maturation) indicates the
extent of intrathymic proliferation [33], which determines the
thymic output of naı ¨ve T cells [34]. In previous studies, this
analysis of ratios has confirmed that sjTREC levels provide a good
indication of thymic output, and are not hugely influenced by
peripheral proliferation [32,33]. Nevertheless the reliability of
measuring sjTRECs to infer thymic output has not yet been
unanimously accepted. Another point to consider when interpret-
ing the TREC data presented here is the higher number of CD4 T
cells in HICs compared to CPs. The causality of higher TREC
levels in HICs compared to CPs is therefore debateable, and may
be due to either increased thymic output replenishing the naı ¨ve T-
cell pool or retention of CD4 T-cells once they are produced or
most likely both. It has also recently been shown that the in vivo
lifespan of effector T-cell subsets is reduced in HIV-1
+ chronic
progressors, compared to healthy controls [35], and it is possible
that the half life of HIV-1-specific effector T cells in HICs is longer
than in chronic progressors. This ability to preserve HIV-1-specific
effector T cells may not be permanent, and a reduction in lifespan
of T cells may precede disease progression.
Another possible reason for eventual disease progression is a
breach in the gut-blood barrier, leading to microbial translocation
and subsequent immune hyperactivation, as described in acute
chronic infection [36]. This breach may result from a decline in
gut cell/tissue regeneration and consequent alteration of the
environment [36]. Both of these areas warrant further investiga-
tion.
The levels of HIV-1 proviral DNA in HICs have been shown to
be approximately 7 times lower than in chronic progressors [24].
Despite undetectable plasma viraemia and lower levels of
integrated provirus, sequencing of HIV-1 proviral gag in an HIC
revealed changes in the DNA sequence over time, which may be
indicative of low level viral turnover [37]. Potential low level
replication, along with the reduction of the proliferative response
to rp24 in this patient, between these two time points, advocates
the possibility that eventually the virus may escape from the
immune control of HICs. However further data on proviral HIV-1
sequences is necessary before any conclusion can be drawn.
The cause and effect relationship of viral load and effective anti-
HIV-1 responses remains debatable. The inability of HIV-1-
specific CD8 T cells to proliferate [7], and load lytic granules is
thought not to be a direct consequence of viral load, as lack of
proliferative and cytolytic potential are not reversed by effective
HAART-mediated suppression of viral load in chronic progressors
as shown here, and previously described [38,39].
Cross-sectional, and (ideally) longitudinal, studies of atypical
patients, such as the HICs presented here, are crucial for the
elucidation of the correlates of progression in HIV-1 disease. By
deciphering what constitutes an effective immune response, we will
know what to endeavor to achieve with therapeutic intervention.
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